EMUC15 - Resource Centre - Search Results

178 results (Loading...)

Video Filters×
  • organe

  • access

  • procedure

  • pathology

178 Abstracts

  • Introduction & ObjectivesDeregulation of FGF-2 expression is a frequent event in prostate cancer. It has previously been suggested that FGF-2 is secreted by stroma cell as paracrine growth factor at early stage of tumour development whereas later stages are characterized by a primarily autocrine secretion that renders tumour cells independent from microenvironmental signaling cues.Material & MethodsWe used a tissue microarray consisting of 571 tumour cores from 165 prostate cancer patients to show that this notion needs to be revisited. An immunohistochemical  protocol was used to assess FGF-2 expression in tumour and stroma cells. Tumour cells and stroma cells were examined and scored separately.ResultsFGF-2 was strongly expressed in tumour cells in %32.1 (53/165) patients and in stroma cells in %16.4 (27/165) patients. We surprisingly found that stromal FGF-2 expression was significantly correlated with poor BCR-free survival (p <0.05) while tumour-associated FGF-2 expression did not predict survival. In addition, higher stromal FGF-2 expression was closely related with Gleason grade (p ≤ 0.005) and clinical stage (p < 0.005). FGF-2 expression levels were found to be related with metastasis in both tumour cells (p<0.05) and stroma cells (p < 0.01).ConclusionsOur results show that microenvironmental effects play a critical role in tumour progression and disease outcomes, moreover these results may be suggested that FGF-2 expression in stroma cells can be used as an independent prognostic factor for prostate cancer. Arslan A.1, Tolstov Y.2, Falkenstein M.2, Roth W.3, Herpel E.3, Grüllich C.4, Teber D.2, Hadaschik B.5, Pahernik S.6, Kristiansen G.7, Hohenfellner M.5, Duensing S.2 7th European Multidisciplinary Meeting on Urological Cancers 1Ege University School of Medicine, Dept. of Internal Medicine, Izmir, 2University of Heidelberg School of Medicine, Dept. of Molecular Urooncology Section, Department of Urology, Heidelberg, 3University of Heidelberg School of Medicine, Dept. of Pathology, Heidelberg, 4National Center For Tumor Diseases (NCT), Dept. of Medical Oncology, Heidelberg, 5University of Heidelberg School of Medicine, Dept. of Urology, Heidelberg, 6University of Heidelberg School of Medicine, Dept.of Urology, Heidelberg, 7University of Bonn School of Medicine, Dept. of Pathology, Heidelberg 58515 EMUC15-0043 P091
  • Introduction & ObjectivesDeregulation of FGF-2 expression is a frequent event in prostate cancer. It has previously been suggested that FGF-2 is secreted by stroma cell as paracrine growth factor at early stage of tumour development whereas later stages are characterized by a primarily autocrine secretion that renders tumour cells independent from microenvironmental signaling cues.Material & MethodsWe used a tissue microarray consisting of 571 tumour cores from 165 prostate cancer patients to show that this notion needs to be revisited. An immunohistochemical  protocol was used to assess FGF-2 expression in tumour and stroma cells. Tumour cells and stroma cells were examined and scored separately.ResultsFGF-2 was strongly expressed in tumour cells in %32.1 (53/165) patients and in stroma cells in %16.4 (27/165) patients. We surprisingly found that stromal FGF-2 expression was significantly correlated with poor BCR-free survival (p <0.05) while tumour-associated FGF-2 expression did not predict survival. In addition, higher stromal FGF-2 expression was closely related with Gleason grade (p ≤ 0.005) and clinical stage (p < 0.005). FGF-2 expression levels were found to be related with metastasis in both tumour cells (p<0.05) and stroma cells (p < 0.01).ConclusionsOur results show that microenvironmental effects play a critical role in tumour progression and disease outcomes, moreover these results may be suggested that FGF-2 expression in stroma cells can be used as an independent prognostic factor for prostate cancer. Arslan A.1, Tolstov Y.2, Falkenstein M.2, Roth W.3, Herpel E.3, Grüllich C.4, Teber D.2, Hadaschik B.5, Pahernik S.6, Kristiansen G.7, Hohenfellner M.5, Duensing S.2 7th European Multidisciplinary Meeting on Urological Cancers 1Ege University School of Medicine, Dept. of Internal Medicine, Izmir, 2University of Heidelberg School of Medicine, Dept. of Molecular Urooncology Section, Department of Urology, Heidelberg, 3University of Heidelberg School of Medicine, Dept. of Pathology, Heidelberg, 4National Center For Tumor Diseases (NCT), Dept. of Medical Oncology, Heidelberg, 5University of Heidelberg School of Medicine, Dept. of Urology, Heidelberg, 6University of Heidelberg School of Medicine, Dept.of Urology, Heidelberg, 7University of Bonn School of Medicine, Dept. of Pathology, Heidelberg 58515 EMUC15-0043 P091
  • Introduction & ObjectivesDeregulation of FGF-2 expression is a frequent event in prostate cancer. It has previously been suggested that FGF-2 is secreted by stroma cell as paracrine growth factor at early stage of tumour development whereas later stages are characterized by a primarily autocrine secretion that renders tumour cells independent from microenvironmental signaling cues.Material & MethodsWe used a tissue microarray consisting of 571 tumour cores from 165 prostate cancer patients to show that this notion needs to be revisited. An immunohistochemical  protocol was used to assess FGF-2 expression in tumour and stroma cells. Tumour cells and stroma cells were examined and scored separately.ResultsFGF-2 was strongly expressed in tumour cells in %32.1 (53/165) patients and in stroma cells in %16.4 (27/165) patients. We surprisingly found that stromal FGF-2 expression was significantly correlated with poor BCR-free survival (p <0.05) while tumour-associated FGF-2 expression did not predict survival. In addition, higher stromal FGF-2 expression was closely related with Gleason grade (p ≤ 0.005) and clinical stage (p < 0.005). FGF-2 expression levels were found to be related with metastasis in both tumour cells (p<0.05) and stroma cells (p < 0.01).ConclusionsOur results show that microenvironmental effects play a critical role in tumour progression and disease outcomes, moreover these results may be suggested that FGF-2 expression in stroma cells can be used as an independent prognostic factor for prostate cancer. Arslan A.1, Tolstov Y.2, Falkenstein M.2, Roth W.3, Herpel E.3, Grüllich C.4, Teber D.2, Hadaschik B.5, Pahernik S.6, Kristiansen G.7, Hohenfellner M.5, Duensing S.2 7th European Multidisciplinary Meeting on Urological Cancers 1Ege University School of Medicine, Dept. of Internal Medicine, Izmir, 2University of Heidelberg School of Medicine, Dept. of Molecular Urooncology Section, Department of Urology, Heidelberg, 3University of Heidelberg School of Medicine, Dept. of Pathology, Heidelberg, 4National Center For Tumor Diseases (NCT), Dept. of Medical Oncology, Heidelberg, 5University of Heidelberg School of Medicine, Dept. of Urology, Heidelberg, 6University of Heidelberg School of Medicine, Dept.of Urology, Heidelberg, 7University of Bonn School of Medicine, Dept. of Pathology, Heidelberg 58515 EMUC15-0043 P091
  • Introduction & ObjectivesDeregulation of FGF-2 expression is a frequent event in prostate cancer. It has previously been suggested that FGF-2 is secreted by stroma cell as paracrine growth factor at early stage of tumour development whereas later stages are characterized by a primarily autocrine secretion that renders tumour cells independent from microenvironmental signaling cues.Material & MethodsWe used a tissue microarray consisting of 571 tumour cores from 165 prostate cancer patients to show that this notion needs to be revisited. An immunohistochemical  protocol was used to assess FGF-2 expression in tumour and stroma cells. Tumour cells and stroma cells were examined and scored separately.ResultsFGF-2 was strongly expressed in tumour cells in %32.1 (53/165) patients and in stroma cells in %16.4 (27/165) patients. We surprisingly found that stromal FGF-2 expression was significantly correlated with poor BCR-free survival (p <0.05) while tumour-associated FGF-2 expression did not predict survival. In addition, higher stromal FGF-2 expression was closely related with Gleason grade (p ≤ 0.005) and clinical stage (p < 0.005). FGF-2 expression levels were found to be related with metastasis in both tumour cells (p<0.05) and stroma cells (p < 0.01).ConclusionsOur results show that microenvironmental effects play a critical role in tumour progression and disease outcomes, moreover these results may be suggested that FGF-2 expression in stroma cells can be used as an independent prognostic factor for prostate cancer. Arslan A.1, Tolstov Y.2, Falkenstein M.2, Roth W.3, Herpel E.3, Grüllich C.4, Teber D.2, Hadaschik B.5, Pahernik S.6, Kristiansen G.7, Hohenfellner M.5, Duensing S.2 7th European Multidisciplinary Meeting on Urological Cancers 1Ege University School of Medicine, Dept. of Internal Medicine, Izmir, 2University of Heidelberg School of Medicine, Dept. of Molecular Urooncology Section, Department of Urology, Heidelberg, 3University of Heidelberg School of Medicine, Dept. of Pathology, Heidelberg, 4National Center For Tumor Diseases (NCT), Dept. of Medical Oncology, Heidelberg, 5University of Heidelberg School of Medicine, Dept. of Urology, Heidelberg, 6University of Heidelberg School of Medicine, Dept.of Urology, Heidelberg, 7University of Bonn School of Medicine, Dept. of Pathology, Heidelberg 58515 EMUC15-0043 P091
  • Introduction & ObjectivesDeregulation of FGF-2 expression is a frequent event in prostate cancer. It has previously been suggested that FGF-2 is secreted by stroma cell as paracrine growth factor at early stage of tumour development whereas later stages are characterized by a primarily autocrine secretion that renders tumour cells independent from microenvironmental signaling cues.Material & MethodsWe used a tissue microarray consisting of 571 tumour cores from 165 prostate cancer patients to show that this notion needs to be revisited. An immunohistochemical  protocol was used to assess FGF-2 expression in tumour and stroma cells. Tumour cells and stroma cells were examined and scored separately.ResultsFGF-2 was strongly expressed in tumour cells in %32.1 (53/165) patients and in stroma cells in %16.4 (27/165) patients. We surprisingly found that stromal FGF-2 expression was significantly correlated with poor BCR-free survival (p <0.05) while tumour-associated FGF-2 expression did not predict survival. In addition, higher stromal FGF-2 expression was closely related with Gleason grade (p ≤ 0.005) and clinical stage (p < 0.005). FGF-2 expression levels were found to be related with metastasis in both tumour cells (p<0.05) and stroma cells (p < 0.01).ConclusionsOur results show that microenvironmental effects play a critical role in tumour progression and disease outcomes, moreover these results may be suggested that FGF-2 expression in stroma cells can be used as an independent prognostic factor for prostate cancer. Arslan A.1, Tolstov Y.2, Falkenstein M.2, Roth W.3, Herpel E.3, Grüllich C.4, Teber D.2, Hadaschik B.5, Pahernik S.6, Kristiansen G.7, Hohenfellner M.5, Duensing S.2 7th European Multidisciplinary Meeting on Urological Cancers 1Ege University School of Medicine, Dept. of Internal Medicine, Izmir, 2University of Heidelberg School of Medicine, Dept. of Molecular Urooncology Section, Department of Urology, Heidelberg, 3University of Heidelberg School of Medicine, Dept. of Pathology, Heidelberg, 4National Center For Tumor Diseases (NCT), Dept. of Medical Oncology, Heidelberg, 5University of Heidelberg School of Medicine, Dept. of Urology, Heidelberg, 6University of Heidelberg School of Medicine, Dept.of Urology, Heidelberg, 7University of Bonn School of Medicine, Dept. of Pathology, Heidelberg 58515 EMUC15-0043 P091
×